355 related articles for article (PubMed ID: 31040850)
21. Induction of immunogenicity by live attenuated Leishmania donovani centrin deleted parasites in dogs.
Fiuza JA; Santiago Hda C; Selvapandiyan A; Gannavaram S; Ricci ND; Bueno LL; Bartholomeu DC; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
Vaccine; 2013 Apr; 31(14):1785-92. PubMed ID: 23398933
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani.
Gamboa-León R; Paraguai de Souza E; Borja-Cabrera GP; Santos FN; Myashiro LM; Pinheiro RO; Dumonteil E; Palatnik-de-Sousa CB
Vaccine; 2006 May; 24(22):4863-73. PubMed ID: 16635538
[TBL] [Abstract][Full Text] [Related]
23. A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
Oliveira-da-Silva JA; Machado AS; Ramos FF; Tavares GSV; Lage DP; Mendonça DVC; Pereira IAG; Santos TTO; Martins VT; Carvalho LM; Freitas CS; Ludolf F; Reis TAR; Bandeira RS; Silva AM; Costa LE; Oliveira JS; Duarte MC; Roatt BM; Teixeira AL; Coelho EAF
Cell Immunol; 2020 Oct; 356():104194. PubMed ID: 32827943
[TBL] [Abstract][Full Text] [Related]
24. Development of dominant epitope-based vaccines encoding Gp63, Kmp-11 and Amastin against visceral leishmaniasis.
Zhang J; He J; Liao X; Xiao Y; Liang C; Zhou Q; Chen H; Zheng Z; Qin H; Chen D; Chen Q; Li J; Chen J
Immunobiology; 2021 May; 226(3):152085. PubMed ID: 33910113
[TBL] [Abstract][Full Text] [Related]
25. Application of rapid in vitro co-culture system of macrophages and T-cell subsets to assess the immunogenicity of dogs vaccinated with live attenuated Leishmania donovani centrin deleted parasites (LdCen-/-).
Viana KF; Fiuza JA; Gannavaram S; Dey R; Selvapandiyan A; Bartholomeu DC; da Silveira-Lemos D; Bueno LL; Dutra WO; Fujiwara RT; Nakhasi HL; Giunchetti RC
Parasit Vectors; 2016 Apr; 9():250. PubMed ID: 27136900
[TBL] [Abstract][Full Text] [Related]
26. A recombinant fusion protein displaying murine and human MHC class I- and II-specific epitopes protects against Leishmania amazonensis infection.
Martins VT; Lage DP; Duarte MC; Carvalho AM; Costa LE; Mendes TA; Vale DL; Menezes-Souza D; Roatt BM; Tavares CA; Soto M; Coelho EA
Cell Immunol; 2017 Mar; 313():32-42. PubMed ID: 28049560
[TBL] [Abstract][Full Text] [Related]
27. Antigenicity and protective efficacy of a Leishmania amastigote-specific protein, member of the super-oxygenase family, against visceral leishmaniasis.
Martins VT; Chávez-Fumagalli MA; Costa LE; Canavaci AM; Martins AM; Lage PS; Lage DP; Duarte MC; Valadares DG; Magalhães RD; Ribeiro TG; Nagem RA; Darocha WD; Régis WC; Soto M; Coelho EA; Fernandes AP; Tavares CA
PLoS Negl Trop Dis; 2013; 7(3):e2148. PubMed ID: 23573301
[TBL] [Abstract][Full Text] [Related]
28. A recombinant chimeric protein composed of human and mice-specific CD4
Martins VT; Duarte MC; Lage DP; Costa LE; Carvalho AM; Mendes TA; Roatt BM; Menezes-Souza D; Soto M; Coelho EA
Parasite Immunol; 2017 Jan; 39(1):. PubMed ID: 27593711
[TBL] [Abstract][Full Text] [Related]
29. Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs.
Nogueira FS; Moreira MA; Borja-Cabrera GP; Santos FN; Menz I; Parra LE; Xu Z; Chu HJ; Palatnik-de-Sousa CB; Luvizotto MC
Vaccine; 2005 Sep; 23(40):4805-10. PubMed ID: 16011864
[TBL] [Abstract][Full Text] [Related]
30. Immuno-informatics based approaches to identify CD8+ T cell epitopes within the Leishmania donovani 3-ectonucleotidase in cured visceral leishmaniasis subjects.
Vijayamahantesh ; Amit A; Dikhit MR; Singh AK; Venkateshwaran T; Das VNR; Das P; Bimal S
Microbes Infect; 2017 Jun; 19(6):358-369. PubMed ID: 28373107
[TBL] [Abstract][Full Text] [Related]
31. Recombinant small glutamine-rich tetratricopeptide repeat-containing protein of Leishmania infantum: Potential vaccine and diagnostic application against visceral leishmaniasis.
Dias DS; Ribeiro PAF; Martins VT; Lage DP; Portela ÁSB; Costa LE; Salles BCS; Lima MP; Ramos FF; Santos TTO; Caligiorne RB; Chávez-Fumagalli MA; Silveira JAG; Magalhães-Soares DF; Gonçalves DU; Oliveira JS; Roatt BM; Duarte MC; Menezes-Souza D; Silva ES; Galdino AS; Machado-de-Ávila RA; Teixeira AL; Coelho EAF
Mol Immunol; 2017 Nov; 91():272-281. PubMed ID: 28988041
[TBL] [Abstract][Full Text] [Related]
32. Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune in Brazilian endemic areas.
Palatnik-de-Sousa CB; Silva-Antunes I; Morgado Ade A; Menz I; Palatnik M; Lavor C
Vaccine; 2009 Jun; 27(27):3505-12. PubMed ID: 19464528
[TBL] [Abstract][Full Text] [Related]
33. Vaccination with a CD4
Dias DS; Ribeiro PAF; Martins VT; Lage DP; Costa LE; Chávez-Fumagalli MA; Ramos FF; Santos TTO; Ludolf F; Oliveira JS; Mendes TAO; Silva ES; Galdino AS; Duarte MC; Roatt BM; Menezes-Souza D; Teixeira AL; Coelho EAF
Transl Res; 2018 Oct; 200():18-34. PubMed ID: 29908151
[TBL] [Abstract][Full Text] [Related]
34. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
[TBL] [Abstract][Full Text] [Related]
35. New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-Virulent
Almeida APMM; Machado LFM; Doro D; Nascimento FC; Damasceno L; Gazzinelli RT; Fernandes AP; Junqueira C
Front Immunol; 2018; 9():465. PubMed ID: 29599776
[TBL] [Abstract][Full Text] [Related]
36. Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis.
Araújo MS; de Andrade RA; Sathler-Avelar R; Magalhães CP; Carvalho AT; Andrade MC; Campolina SS; Mello MN; Vianna LR; Mayrink W; Reis AB; Malaquias LC; Rocha LM; Martins-Filho OA
Vet Immunol Immunopathol; 2011 May; 141(1-2):64-75. PubMed ID: 21439654
[TBL] [Abstract][Full Text] [Related]
37. Heterologous Immunization With Defined RNA and Subunit Vaccines Enhances T Cell Responses That Protect Against
Duthie MS; Van Hoeven N; MacMillen Z; Picone A; Mohamath R; Erasmus J; Hsu FC; Stinchcomb DT; Reed SG
Front Immunol; 2018; 9():2420. PubMed ID: 30386348
[TBL] [Abstract][Full Text] [Related]
38. Antibody responses induced by Leish-Tec®, an A2-based vaccine for visceral leishmaniasis, in a heterogeneous canine population.
Testasicca MC; dos Santos MS; Machado LM; Serufo AV; Doro D; Avelar D; Tibúrcio AM; Abrantes Cde F; Machado-Coelho GL; Grimaldi G; Gazzinelli RT; Fernandes AP
Vet Parasitol; 2014 Aug; 204(3-4):169-76. PubMed ID: 24863572
[TBL] [Abstract][Full Text] [Related]
39. Comparison of two commercial vaccines against visceral leishmaniasis in dogs from endemic areas: IgG, and subclasses, parasitism, and parasite transmission by xenodiagnosis.
Fernandes CB; Junior JT; de Jesus C; Souza BM; Larangeira DF; Fraga DB; Tavares Veras PS; Barrouin-Melo SM
Vaccine; 2014 Mar; 32(11):1287-95. PubMed ID: 24406392
[TBL] [Abstract][Full Text] [Related]
40. Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.
Petitdidier E; Pagniez J; Papierok G; Vincendeau P; Lemesre JL; Bras-Gonçalves R
PLoS Negl Trop Dis; 2016 May; 10(5):e0004614. PubMed ID: 27223609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
